ME Newswire / Business Wire
SAN DIEGO - Tuesday, March 4th 2014
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced it has added Illumina NextSeq 500 systems to its force of NGS sequencers, enhancing the company’s established and highly efficient laboratory processes.
The NextSeq 500’s push-button operation provides a one-day turnaround time for an array of popular sequencing applications such as a single human genome, and up to 16 exomes, 20 transcriptomes, 48 gene expression samples, 20 non-invasive prenatal samples, and 96 targeted panels. Additionally, with the sequencer’s streamlined informatics, sequencing data can be run through a range of commercial pipelines.
"The addition of this advanced next-generation sequencing system provides our clinical laboratory with another powerful tool in the NGS space, adding to our current capabilities,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer. "Our primary objective is to provide physicians and their patients with accurate laboratory results in a timely manner, and the NextSeq 500 is a key factor in taking us to a new level in meeting that goal.”
Delivering the power of high-throughput sequencing with the load-and-go simplicity of a desktop sequencer, the NextSeq 500 is the only NGS system capable of sequencing a whole human genome at high coverage in one run.
"Acquiring the first Illumina NextSeq 500 sequencers sets our company apart from other competitors in the clinical diagnostic space,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. "Speed, efficiency and accuracy are key for us, and the NextSeq 500 is currently the fastest sequencer to produce results for genomes, exomes and targeted resequencing right off the bench.”
About Pathway Genomics Corporation
As a CLIA and CAP accredited clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cardiac health, cancer risk, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.
Contacts
Pathway Genomics Corporation
Zak Pugh, 858-217-4358
pr@pathway.com
www.pathway.com
Permalink: http://me-newswire.net/news/10211/en
|
